Cancer immunoprevention - The next frontier

Marie Anne D. Smit, Elizabeth M. Jaffee, Eric R. Lutz

Research output: Contribution to journalArticlepeer-review

Abstract

Cancer immunotherapy is a rapidly developing field, but limited in its success by a high tumor burden and immune tolerance. In contrast, immunoprevention has the potential to prevent cancer before the development of immune tolerance, and to prevent cancer recurrence in the setting of minimal residual disease. Although immunoprevention for viral-induced cancers has been successful in the setting of hepatitis B and human papillomavirus vaccination, primary prevention of nonviral-induced cancers is in its infancy. In contrast, prevention of cancer recurrence after adjuvant treatment (secondary prevention) is gaining steam. This review provides an overview of the scope of research in cancer immunoprevention over the last three years and directions for future research.

Original languageEnglish (US)
Pages (from-to)1072-1080
Number of pages9
JournalCancer Prevention Research
Volume7
Issue number11
DOIs
StatePublished - Nov 1 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cancer immunoprevention - The next frontier'. Together they form a unique fingerprint.

Cite this